313654-83-0

Basic information

• Product Name: 3'-CHLORO-2,3,5,6-TETRAHYDRO-[1,2']BIPYRAZINYL-4-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3'-CHLORO-2,3,5,6-TETRAHYDRO-[1,2']BIPYRAZINYL-4-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 4-(3-chloropyrazin-2-yl)piperazine-1-carboxylate;2']bipyrazinyl-4-carboxylic acid tert-butyl ester;3'-Chloro-2;6-tetrahydro-[1;2-Chloro-3-(4-tert-butoxycarbonyl-1-piperazinyl)pyrazine;4-(3-chloro-2-pyrazinyl)-1-piperazinecarboxylic acid tert-butyl ester;4-(3-chloropyrazin-2-yl)piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 313654-83-0
• Molecular Formula: C₁₃H₁₉ClN₄O₂
• Molecular Weight: 298.77
• Mol File: 313654-83-0.mol

Chemical Properties

• Boiling Point: 412.8°Cat760mmHg
• Flash Point: 203.4°C
• Appearance: /
• Density: 1.253g/cm³
• Vapor Pressure: 5.06E-07mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3'-CHLORO-2,3,5,6-TETRAHYDRO-[1,2']BIPYRAZINYL-4-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-CHLORO-2,3,5,6-TETRAHYDRO-[1,2']BIPYRAZINYL-4-CARBOXYLIC ACID TERT-BUTYL ESTER(313654-83-0)
• EPA Substance Registry System: 3'-CHLORO-2,3,5,6-TETRAHYDRO-[1,2']BIPYRAZINYL-4-CARBOXYLIC ACID TERT-BUTYL ESTER(313654-83-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 313654-83-0(Hazardous Substances Data)

Usage

Uses

3''-Chloro-2,3,5,6-tetrahydro-[1,2'']bipyrazinyl-4-carboxylic Acid tert-Butyl Ester

InChI:InChI=1/C13H19ClN4O2/c1-13(2,3)20-12(19)18-8-6-17(7-9-18)11-10(14)15-4-5-16-11/h4-5H,6-9H2,1-3H3

Upstream product

• 4858-85-9 2,3-dichloropyrazine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1082063-19-1 2-{4-[3'-(4-methoxymethyl-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-ylmethyl]-pyrazol-1-yl}-ethanol hydrochloride 
• 1082063-12-4 {4-[4-(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-yl]-phenyl}-methanol hydrochloride 
• 1082063-65-7 methyl 4-(3-(4-((1,3-dimethyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)pyrazin-2-yl)benzoate hydrochloride 
• 1082066-12-3 3'-chloro-4-(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazine 
• 1082066-14-5 2-[4-(3'-chloro-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-ylmethyl)-pyrazol-1-yl]-ethanol 
• 1082066-10-1 3'-chloro-4-(1,3-dimethyl-1H-pyrazol-4-ylmethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazine 
• 1082065-40-4 4-(3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-yl)-benzonitrile 
• 1082066-11-2 3'-chloro-4-(1-methyl-1H-pyrazol-4-ylmethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazine 
• 1082065-20-0 3'-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazine 
• 1377550-27-0 5-(3-(4-(3-(4-methoxyphenyl)pyrazin-2-yl)piperazin-1-ylsulfonyl)phenyl)pyrimidin-2-amine 
• 1377551-51-3 2-(4-methoxyphenyl)-3-(4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylsulfonyl)piperazin-1-yl)pyrazine 
• 1377551-34-2 C₂₁H₂₁BrN₄O₃S 
• 1377550-22-5 2-(4-(4'-methoxybiphenyl-3-ylsulfonyl)piperazin-1-yl)-3-(4-methoxyphenyl)pyrazine 
• 1377551-31-9 C₁₄H₁₄BrClN₄O₂S 

Relevant articles and documents

NOVEL COMPOUNDS AS ROR GAMMA MODULATORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula (I) and their use in the treatment of migraine: where A is C(H)= or N=; m is 0, 1 or 2; R1 is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or thienyl; R2 is hydrogen or methyl; and R3 and R4 are as defined herein.

5-HT7 RECEPTOR ANTAGONISTS

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is C(H)= or -N= and R1-7 are as defined herein.

2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)= or N=, provided that at least one of A and B is -N=, n is 1-3, m is 0-3, and R14 are as defined herein.

PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE

The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (whereinR1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like,R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like,R5: hydrogen, a lower alkyl, a lower alkoxycarbonyl, or the like, andn: 0 or 1).

Novel compounds and their use

The invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as described in the specification, which compounds are ligands to the serotonin 5-HT2c receptor.

Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

Compounds of the general formula (I): wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2creceptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.